Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- GLP-1s linked to better IBD outcomes, hinting at role as ‘valuable adjunctive therapies’ (Healio)
- The cyber siege of private practices: Are you at risk? (Medical Economics)
- Is The Galleri Cancer Test Worth It? A Doctor Explains (Forbes)
- With a little help from my friends: What gastrointestinal pathologists need to know from gastroenterologists (GI & Hepatology News)
- The GI innovations transforming outcomes (Becker’s GI & Endoscopy)
- The Smart Toilet: Turning Waste Into Health Insights – Dr. Sonia Grego, Ph.D. (Progress, Potential, and Possibilities | YouTube)
- Peripheral gaze guidance improves adenoma detection rate (GI & Hepatology News)
- Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus (American Journal of Gastroenterology)
